Does Dr. LAYLA ABDUL JABBAR have financial conflicts of interest?

Dr. LAYLA ABDUL JABBAR (MD) has received a total of $355 in pharmaceutical and medical device industry funding between 2021 and 2025. This includes $355 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. LAYLA ABDUL JABBAR?

According to CMS Open Payments data, Dr. LAYLA ABDUL JABBAR received funding from MADRIGAL PHARMACEUTICALS ($172), ASCENDIS PHARMA ENDOCRINOLOGY ($122), and AMGEN ($41).

Does Dr. LAYLA ABDUL JABBAR receive research grants or speaking fees?

Dr. LAYLA ABDUL JABBAR has received $355 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. LAYLA ABDUL JABBAR

MDReal-Time Hydrated

Specialty: Internal Medicine

Practice Location: GALVESTON, TX 77555

NPI Number: 1790469559

LIFETIME INDUSTRY VALUE

$355

2021 – 2025 Cumulative

Conflict of Interest Analysis

Dr. ABDUL JABBAR is a verified Internal Medicine practitioner based in GALVESTON, TX.

Between 2021 and 2025, Dr. ABDUL JABBAR had an overall industry promotional and research financial footprint of $355 as recorded in the federal CMS Open Payments database.

$355 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. ABDUL JABBAR's primary funding source is MADRIGAL PHARMACEUTICALS, which accounts for $172 (representing 48.4% of overall industry footprint).

Data coverage: 2021 – 2025 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

MADRIGAL PHARMACEUTICALS

Rank 1

$172

48.4%

ASCENDIS PHARMA ENDOCRINOLOGY

Rank 2

$122

34.4%

AMGEN

Rank 3

$41

11.5%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2025

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.